JP2020500525A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500525A5 JP2020500525A5 JP2019529260A JP2019529260A JP2020500525A5 JP 2020500525 A5 JP2020500525 A5 JP 2020500525A5 JP 2019529260 A JP2019529260 A JP 2019529260A JP 2019529260 A JP2019529260 A JP 2019529260A JP 2020500525 A5 JP2020500525 A5 JP 2020500525A5
- Authority
- JP
- Japan
- Prior art keywords
- chain
- tcr
- modified
- βr44d
- βq44r
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (12)
- 非修飾αおよび/またはβ鎖のIMGT番号付けによる44位のアミノ酸が、修飾α鎖および/またはβ鎖と、修飾されていない望まれないαまたはβ鎖との対合を減少させる、アミノ酸R、D、E、K、L、W、およびVからなる群から選択されるアミノ酸によって置換されている、抗原−MHC複合体に結合する能力を維持する、修飾T細胞受容体(TCR)α鎖および/もしくはβ鎖、またはその断片もしくは誘導体。
- 前記修飾α鎖が、配列番号1または3と少なくとも95%の配列同一性を有する配列のフレームワーク領域を少なくとも含んでなる可変ドメイン配列を有し、および/または前記修飾β鎖が、配列番号2または4と少なくとも95%の配列同一性を有する配列のフレームワーク領域を含んでなる可変ドメイン配列を有する、請求項1に記載の修飾T細胞受容体(TCR)α鎖またはβ鎖。
- 前記TCRが抗原−MHC複合体と結合する能力を維持する、請求項1または2に記載の修飾α鎖および/または修飾β鎖、またはその断片もしくは誘導体を含んでなる、組換えT細胞受容体(TCR)ヘテロ二量体。ここで、前記そのαおよび/またはβ鎖の修飾は、Q、R、D、E、K、L、W、およびVからなる群から選択されるアミノ酸による44位の置換から選択される。
- 前記α鎖およびβ鎖の前記修飾が、αQ44D/βQ44R;αQ44R/βQ44D;αQ44E/βQ44K;αQ44K/βQ44E;αQ44D/βQ44K;αQ44K/βQ44D;αQ44E/βQ44R;αQ44R/βQ44E;αQ44L/βQ44W;αQ44W/βQ44L;αQ44V/βQ44W;αQ44W/βQ44V;αW44D/βQ44R;αW44R/βQ44D;αW44E/βQ44K;αW44K/βQ44E;αW44D/βQ44K;αW44K/βQ44D;αW44E/βQ44R;αW44R/βQ44E;αW44L/βQ44W;αW44/βQ44L;αW44V/βQ44W;αW44/βQ44V;αH44D/βQ44R;αH44R/βQ44D;αH44E/βQ44K;αH44K/βQ44E;αH44D/βQ44K;αH44K/βQ44D;αH44E/βQ44R;αH44R/βQ44E;αH44L/βQ44W;αH44W/βQ44L;αH44V/βQ44W;αH44W/βQ44V;αK44D/βQ44R;αK44R/βQ44D;αK44E/βQ44K;αK44/βQ44E;αK44D/βQ44K;αK44/βQ44D;αK44E/βQ44R;αK44R/βQ44E;αK44L/βQ44W;αK44W/βQ44L;αK44V/βQ44W;αK44W/βQ44V;αE44D/βQ44R;αE44R/βQ44D;αE44/βQ44K;αE44K/βQ44E;αE44D/βQ44K;αE44K/βQ44D;αE44/βQ44R;αE44R/βQ44E;αE44L/βQ44W;αE44W/βQ44L;αE44V/βQ44W;αE44W/βQ44V;αQ44D/βR44;αQ44R/βR44D;αQ44E/βR44K;αQ44K/βR44E;αQ44D/βR44K;αQ44K/βR44D;αQ44E/βR44;αQ44R/βR44E;αQ44L/βR44W;αQ44W/βR44L;αQ44V/βR44W;αQ44W/βR44V;αW44D/βR44;αW44R/βR44D;αW44E/βR44K;αW44K/βR44E;αW44D/βR44K;αW44K/βR44D;αW44E/βR44;αW44R/βR44E;αW44L/βR44W;αW44/βR44L;αW44V/βR44W;αW44/βR44V;αH44D/βR44;αH44R/βR44D;αH44E/βR44K;αH44K/βR44E;αH44D/βR44K;αH44K/βR44D;αH44E/βR44;αH44R/βR44E;αH44L/βR44W;αH44W/βR44L;αH44V/βR44W;αH44W/βR44V;αK44D/βR44;αK44R/βR44D;αK44E/βR44K;αK44/βR44E;αK44D/βR44K;αK44/βR44D;αK44E/βR44;αK44R/βR44E;αK44L/βR44W;αK44W/βR44L;αK44V/βR44W;αK44W/βR44V;αE44D/βR44;αE44R/βR44D;αE44/βR44K;αE44K/βR44E;αE44D/βR44K;αE44K/βR44D;αE44R/βR44E;αE44L/βR44W;αE44W/βR44L;αE44V/βR44W;およびαE44W/βR44Vからなる群の置換対から選択され、好ましくはα44D/β44R;α44R/β44D;α44E/β44K;α44K/β44E;α44D/β44K;α44K/β44D;α44E/β44R;およびα44R/β44Eからなる群から選択される、請求項3に記載の組換えT細胞受容体(TCR)ヘテロ二量体。
- 前記TCRの前記α鎖が、配列番号1または3と少なくとも95%の配列同一性を有する配列のフレームワーク領域を少なくとも含んでなる可変ドメイン配列を有し、および/または前記TCRの前記β鎖が、配列番号2または4と少なくとも95%の配列同一性を有する配列のフレームワーク領域を含んでなる可変ドメイン配列を有する、請求項3または4に記載の組換えT細胞受容体(TCR)ヘテロ二量体。
- 請求項1または2に記載の修飾T細胞受容体(TCR)α鎖またはβ鎖、および/または請求項3〜5のいずれか一項に記載の組換えT細胞受容体(TCR)ヘテロ二量体をコ−ドする核酸分子。
- 請求項6に記載の核酸分子の少なくとも1つを含んでなる、プラスミドまたは発現ベクタ−。
- 請求項6に記載の1つまたは複数の核酸分子、または請求項7に記載のプラスミドもしくは発現ベクタ−で、対象補助から得られたT細胞を形質導入または形質移入するステップを含んでなる、修飾T細胞を調製する方法。
- 請求項8に従って生成される、修飾T細胞。
- それを必要とする対象の自己由来T細胞療法で使用するための、請求項9に記載の修飾T細胞。
- 前記それを必要とする対象に、前記修飾T細胞を含んでなる製剤を投与するステップを含んでなる、新生物疾患、炎症性疾患、感染性疾患もしくは自己免疫疾患に罹患している、またはそれらを発症するリスクがある、および/またはそれらであると診断された、治療を必要とする対象の治療で使用するための請求項9に記載の修飾T細胞。
- 請求項3または4に記載の組換えT細胞受容体(TCR)ヘテロ二量体であって、前記TCRがMHC複合体によって提示される抗原に特異的に結合し、前記抗原が腫瘍関連抗原(TAA)のエピト−プから選択される、組換えT細胞受容体(TCR)ヘテロ二量体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023010833A JP2023052688A (ja) | 2016-12-08 | 2023-01-27 | 対合が改善されたt細胞受容体t細胞 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662497895P | 2016-12-08 | 2016-12-08 | |
US62/497,895 | 2016-12-08 | ||
DE102016123893.7A DE102016123893A1 (de) | 2016-12-08 | 2016-12-08 | T-Zellrezeptoren mit verbesserter Bindung |
DE102016123893.7 | 2016-12-08 | ||
PCT/EP2017/081745 WO2018104407A1 (en) | 2016-12-08 | 2017-12-06 | T cell receptors with improved pairing |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023010833A Division JP2023052688A (ja) | 2016-12-08 | 2023-01-27 | 対合が改善されたt細胞受容体t細胞 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020500525A JP2020500525A (ja) | 2020-01-16 |
JP2020500525A5 true JP2020500525A5 (ja) | 2020-05-07 |
JP7346294B2 JP7346294B2 (ja) | 2023-09-19 |
Family
ID=62201182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019529260A Active JP7346294B2 (ja) | 2016-12-08 | 2017-12-06 | 対合が改善されたt細胞受容体t細胞 |
Country Status (14)
Country | Link |
---|---|
US (2) | US11072645B2 (ja) |
EP (1) | EP3551653B1 (ja) |
JP (1) | JP7346294B2 (ja) |
CN (1) | CN110099923A (ja) |
AU (1) | AU2017371260C1 (ja) |
BR (1) | BR112019010803A2 (ja) |
CA (1) | CA3045230A1 (ja) |
CR (1) | CR20190280A (ja) |
DE (1) | DE102016123893A1 (ja) |
MA (1) | MA47359A (ja) |
MX (1) | MX2019006726A (ja) |
PE (1) | PE20191150A1 (ja) |
TW (1) | TWI710572B (ja) |
WO (1) | WO2018104407A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
ES2916092T3 (es) | 2016-12-08 | 2022-06-28 | Immatics Biotechnologies Gmbh | Nuevos receptores de linfocitos T e inmunoterapias basadas en el uso de los mismos |
DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
ES2941965T3 (es) | 2017-11-06 | 2023-05-29 | Immatics Biotechnologies Gmbh | Nuevos receptores de linfocito T genomanipulados e inmunoterapias basadas en el uso de los mismos |
DE102017125888A1 (de) | 2017-11-06 | 2019-05-23 | Immatics Biotechnologies Gmbh | Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie |
WO2020191172A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
DE102019108125B4 (de) | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
SG11202112860PA (en) | 2019-05-27 | 2021-12-30 | Immatics Us Inc | Viral vectors and their use in adoptive cellular therapy |
DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
US20230132241A1 (en) | 2020-01-15 | 2023-04-27 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
AU2021225817A1 (en) | 2020-02-24 | 2022-10-20 | Immatics US, Inc. | Methods for expanding T cells for the treatment of cancer and related malignancies |
DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
US20220056411A1 (en) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Methods for isolating cd8+ selected t cells |
CA3203118A1 (en) | 2020-12-31 | 2022-07-07 | Gagan BAJWA | Cd8 polypeptides, compositions, and methods of using thereof |
WO2022184805A1 (en) | 2021-03-03 | 2022-09-09 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein |
TW202309071A (zh) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合prame之抗原結合蛋白 |
KR20240038028A (ko) | 2021-07-27 | 2024-03-22 | 이매틱스 바이오테크놀로지스 게엠베하 | Ct45에 특이적으로 결합하는 항원 결합 단백질 |
WO2023044488A1 (en) | 2021-09-20 | 2023-03-23 | Immatics US, Inc. | Monocyte depletion of t cells populations for t-cell therapy |
US20230192886A1 (en) | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
US20230142468A1 (en) | 2021-11-08 | 2023-05-11 | Immatics US, Inc. | Methods for generating cell spheroids |
EP4198052A1 (en) | 2021-12-15 | 2023-06-21 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers |
US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
WO2023212691A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF |
US20230348548A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
US20230355678A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2244744A1 (en) * | 1996-02-01 | 1997-08-07 | University Of Florida | Lyst1 and lyst2 gene compositions and methods of use |
DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
DE10313819A1 (de) | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
US7811828B2 (en) | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
EP1717245B1 (en) | 2005-04-26 | 2011-06-08 | Immatics Biotechnologies GmbH | T-cell epitopes from the oncofetal antigen-immature laminin receptor protein and medical uses thereof |
SI1760089T1 (sl) | 2005-09-05 | 2009-12-31 | Immatics Biotechnologies Gmbh | S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku |
ES2302546T3 (es) | 2005-09-05 | 2008-07-16 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores, que se enlazan a diferentes antigenos de leucocitos humanos (hla) de la clase ii. |
SI2183361T1 (sl) | 2007-07-27 | 2015-09-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti nevronalnim in možganskim tumorjem |
EP2562182B1 (en) | 2007-07-27 | 2015-10-07 | Immatics Biotechnologies GmbH | Novel immunogenic epitopes for immunotherapy |
CN103360466B (zh) | 2007-07-27 | 2016-08-03 | 伊玛提克斯生物技术有限公司 | 抗肿瘤相关肽及相关抗癌疫苗组合物 |
EP2288700B1 (en) * | 2008-05-09 | 2017-02-08 | Agency for Science, Technology And Research | Hbv epitope reactive exogenous t cell receptor (tcr) and uses thereof |
PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
PL2172211T3 (pl) | 2008-10-01 | 2015-05-29 | Immatics Biotechnologies Gmbh | Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka |
GB0917094D0 (en) * | 2009-09-29 | 2009-11-11 | Ucl Biomedica Plc | T-cell receptor |
WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
GB201015765D0 (en) | 2010-09-21 | 2010-10-27 | Immatics Biotechnologies Gmbh | Use of myeloid cell biomarkers for the diagnosis of cancer |
GB201021289D0 (en) | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
MX2013006758A (es) | 2010-12-14 | 2013-08-01 | Immatics Biotechnologies Gmbh | Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos. |
GB2508414A (en) | 2012-11-30 | 2014-06-04 | Max Delbrueck Centrum | Tumour specific T cell receptors (TCRs) |
CA2906970C (en) | 2013-03-21 | 2021-05-18 | Ospedale San Raffaele Srl | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
TWI714869B (zh) | 2013-08-05 | 2021-01-01 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物 |
PE20150600A1 (es) | 2013-10-15 | 2015-06-03 | Vignolo Carlos Alberto Ibanez | CICLO - BICICLETA HIBRIDA MOTORIZADA 2 x 2 |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
GB2528124A (en) | 2014-07-11 | 2016-01-13 | Nec Corp | Communication system |
TWI617841B (zh) | 2014-10-22 | 2018-03-11 | 英特爾股份有限公司 | 用於光學系統的防雲紋圖樣擴散器 |
WO2016064317A1 (en) | 2014-10-24 | 2016-04-28 | Telefonaktiebolaget L M Ericsson (Publ) | Method and arrangement for csi-rs transmission |
CN104460328B (zh) | 2014-10-29 | 2019-05-10 | 小米科技有限责任公司 | 基于设定场景模式的智能设备控制方法和装置 |
DE102014016105A1 (de) | 2014-10-30 | 2016-05-04 | Head Technology Gmbh | Superelastische Schlägersaite |
TWI687511B (zh) | 2014-10-30 | 2020-03-11 | 美商艾科詹瑟斯有限公司 | 由混合固體廢棄物形成之固體燃料組合物 |
US20190030071A1 (en) | 2014-11-03 | 2019-01-31 | IMMURES S.r.I. | T cell receptors |
MA40904A (fr) | 2014-11-03 | 2017-09-12 | Hygeia Tech Inc | Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie |
US10786360B2 (en) | 2014-11-04 | 2020-09-29 | Spinal Stabilization Technologies Llc | Percutaneous implantable nuclear prosthesis |
US10543081B2 (en) | 2014-11-17 | 2020-01-28 | Mitrassist Medical Ltd. | Heart valve prosthesis |
KR20170054544A (ko) | 2014-11-20 | 2017-05-17 | 에이비비 슈바이쯔 아게 | 전자기 브레이크 시스템 및 금속 제조 프로세스에서 용융 금속 유동을 제어하는 방법 |
DE102014223758A1 (de) | 2014-11-20 | 2016-05-25 | Windmöller & Hölscher Kg | Kontaktwalze |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
EP3067366A1 (en) | 2015-03-13 | 2016-09-14 | Max-Delbrück-Centrum Für Molekulare Medizin | Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 |
GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
MY189596A (en) | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
GB201515321D0 (en) | 2015-08-28 | 2015-10-14 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
MA45004A (fr) | 2015-10-09 | 2019-03-27 | Immatics Biotechnologies Gmbh | Anticorps spécifiques anti-wt1-hla |
GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
-
2016
- 2016-12-08 DE DE102016123893.7A patent/DE102016123893A1/de active Pending
-
2017
- 2017-12-06 WO PCT/EP2017/081745 patent/WO2018104407A1/en unknown
- 2017-12-06 CN CN201780075297.XA patent/CN110099923A/zh active Pending
- 2017-12-06 CA CA3045230A patent/CA3045230A1/en active Pending
- 2017-12-06 MA MA047359A patent/MA47359A/fr unknown
- 2017-12-06 BR BR112019010803A patent/BR112019010803A2/pt unknown
- 2017-12-06 PE PE2019001163A patent/PE20191150A1/es unknown
- 2017-12-06 US US15/833,778 patent/US11072645B2/en active Active
- 2017-12-06 JP JP2019529260A patent/JP7346294B2/ja active Active
- 2017-12-06 EP EP17825761.4A patent/EP3551653B1/en active Active
- 2017-12-06 AU AU2017371260A patent/AU2017371260C1/en active Active
- 2017-12-06 MX MX2019006726A patent/MX2019006726A/es unknown
- 2017-12-06 CR CR20190280A patent/CR20190280A/es unknown
- 2017-12-08 TW TW106143062A patent/TWI710572B/zh not_active IP Right Cessation
-
2021
- 2021-06-22 US US17/354,555 patent/US20210380659A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020500525A5 (ja) | ||
TWI710572B (zh) | 改善配對的t細胞受體 | |
ES2916092T3 (es) | Nuevos receptores de linfocitos T e inmunoterapias basadas en el uso de los mismos | |
TWI775768B (zh) | 新穎t細胞受器及使用其之免疫治療 | |
JP6615612B2 (ja) | 新規腫瘍特異的t細胞レセプター | |
ES2734190T3 (es) | Receptores de linfocitos T | |
ES2784237T3 (es) | Receptores de células T anti-papilomavirus 16 E7 humano | |
JP2020500523A5 (ja) | ||
WO2021068938A1 (zh) | 一种识别kras突变的t细胞受体及其编码序列 | |
JP2016505635A5 (ja) | ||
JP2019511222A5 (ja) | ||
WO2016177339A1 (zh) | 识别ny-eso-1抗原短肽的t细胞受体 | |
JP2018501794A5 (ja) | ||
JP2018530331A5 (ja) | ||
TW201828977A (zh) | 新穎t細胞受體以及使用彼之免疫療法 | |
JP2019522490A5 (ja) | ||
JP2019059786A5 (ja) | ||
JP2019516665A5 (ja) | ||
JP2016528244A (ja) | T細胞レセプター | |
JP2016505635A (ja) | Mage−a1を認識する高結合活性結合分子 | |
JP2015518479A5 (ja) | ||
JP2017501129A5 (ja) | ||
JP2020512019A5 (ja) | ||
JP2013505734A5 (ja) | ||
JP2019509054A5 (ja) |